NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

Inclusion Criteria

- Cognitive function scores consistent with amnestic mild cognitive impairment based on
pre-screening evaluation;

- age 60-90 years;

- MMSE score >24 at time of initial consent;

Exclusion Criteria

- blood chemistries indicative of abnormal renal, liver, thyroid and adrenal function;
estimated glomerular filtration rate using the MDRD prediction equation must be >60
ml/min/1.73 m2;

- any clinically significant abnormal blood chemistry values as determined by the
research nurse or NMPCC nurse practitioner;

- major psychiatric disorder (e.g. schizophrenia, bipolar disorder, major depression
within past two years);

- neurological or autoimmune conditions affecting cognition (e.g. Parkinson's disease,
epilepsy, multiple sclerosis, mild or severe traumatic brain injury, large vessel
infarct);

- concussion within last 2 years and ≥ 3 lifetime concussions;

- systemic medical illnesses (e.g. cardiovascular disease, cancer, renal failure);

- substance abuse or dependence (DSM-V criteria);

- current use of medications used to treat dementia (e.g., anticholinesterase drugs) or
other drugs likely to affect cognition (e.g., anticholinergic drugs, long-acting
benzodiazepines);

- claustrophobia, metal implants, pacemaker or other factors affecting feasibility
and/or safety of MRI scanning*;

- current smoking (including marijuana) within the past 3 months